HYOSCINE BUTYLBROMIDE INJECTION BP SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

HYOSCINE BUTYLBROMIDE

Disponibbli minn:

OMEGA LABORATORIES LIMITED

Kodiċi ATC:

A03BB01

INN (Isem Internazzjonali):

BUTYLSCOPOLAMINE

Dożaġġ:

20MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

HYOSCINE BUTYLBROMIDE 20MG

Rotta amministrattiva:

INTRAMUSCULAR

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANTIMUSCARINICS ANTISPASMODICS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0104703002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2020-11-23

Karatteristiċi tal-prodott

PRESCRIBING INFORMATION AND
PATIENT MEDICATION INFORMATION
PR
HYOSCINE BUTYLBROMIDE INJECTION BP
20 mg/mL
Sterile Solution
Antispasmodic
Omega Laboratories Ltd.
Date of Preparation: November 20, 2020
11177 Hamon
Montreal, Quebec, H3M 3E4
Submission Control No.: 235093
_Hyoscine Butylbromide Injection BP _
_Page 2 of 18 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
............................................................................................................
6
DRUG INTERACTIONS
.............................................................................................................
7
DOSAGE AND ADMINISTRATION
.........................................................................................
8
OVERDOSAGE
...........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
10
STORAGE AND STABILITY
..................................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................................... 11
PART II: SCIENTIFIC INFORMATION
................................................................................
12
PHARMACEUTICAL INFORMATION
..................................................................................
12
REFERENCES
..............................................